4 results

• O-GlcNAcylation

  A reversible post-translational modification in which an N-acetylglucosamine (GlcNAc) molecule is added to a protein, regulating its folding, phosphorylation, and degradation. Increased O-GlcNAcylation of tau may counterbalance hyperphosphorylation and promote neuronal survival.

  Reference:

  Permanne B, Sand A, Ousson S, et al. O-GlcNAcase inhibitor ASN90 is a multimodal drug candidate for tau and α-synuclein proteinopathies. ACS Chem Neurosci. 2022;13(8):1296-1314. doi:10.1021/acschemneuro.2c00057

• Ocular motor dysfunction

  Abnormalities in controlling eye movements, affecting gaze stability and visual tracking.

  Reference:

  Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853-864. doi:10.1002/mds.26987

• OGA inhibitor

  A molecule that inhibits O-GlcNAcase, increasing protein O-GlcNAcylation and reducing phosporilation, proposed to restore tau homeostasis and reduce neurodegeneration in PSP (i.e. Egalognastat / FNP-223).

  Reference:

  Permanne B, Sand A, Ousson S, et al. O-GlcNAcase inhibitor ASN90 is a multimodal drug candidate for tau and α-synuclein proteinopathies. ACS Chem Neurosci. 2022;13(8):1296-1314. doi:10.1021/acschemneuro.2c00057

• Oligodendroglial coiled bodies

  Abnormal tau-positive inclusions found within the cytoplasm of oligodendrocytes.

  Reference:

  Komori T. Pathology of oligodendroglia: an overview. Neuropathology. 2017;37(5):465-474. doi:10.1111/neup.12389